In vivo binding of the radioiodinated peptide YIGSR on B16 melanoma cells.
It has been reported that metastatic melanoma cell lines selectively bind in vitro with the synthetic laminin pentapeptide tyrosyl-isoleucyl-glycyl-seryl-arginine (YIGSR). The aim of this study was to investigate whether the same peptide can bind on melanoma cells in vivo as well. Iodine-125-labeled YIGSR was administered to B16 melanoma-bearing animals. Microscopic autoradiography of tumor and organ sections taken 24 h after peptide administration showed that the peptide did accumulate on the surface of certain tumor cells. The peptide binding cells were frequent in metastatic sites and tumors grown for 24 days and rare in tumors grown for 10 days. A similarly radiolabeled control pentapeptide (peptide DRLKY) did not bind to any tumor cell. It is suggested that the YIGSR binding tumor cells may represent a distinct melanoma cell population with a high metastatic potential.
Kouzi-Koliakos
K
K
Department of Histology and Embryology, AHEPA General Hospital, Medical School Aristotle University of Thessaloniki, Greece. koliakos@hyper.gr
Koliakos
G
G
Trontzos
C
C
Papageorgiou
A
A
Iliadis
S
S
Triantos
A
A
Dimitriadou
A
A
Kanellaki
M
M
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D001345:Autoradiography; D007457:Iodine Radioisotopes; D008546:Melanoma, Experimental / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009842:Oligopeptides / Q000378:metabolism*
D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D009842:Oligopeptides; C081571:tyrosyl-isoleucyl-glycyl-seryl-arginine